



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/508,570	05/23/2000	Francois Arminjon	MBHIB00-210	9141

7590 05/15/2002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

EXAMINER

BROWN, STACY S

ART UNIT	PAPER NUMBER
1648	11

DATE MAILED: 05/15/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/508,570	ARMINJON ET AL.
	Examiner	Art Unit
	Stacy S Brown	1648

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 02 May 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) The period for reply expires ____ months from the mailing date of the final rejection.
- b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
 - (a) they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) they raise the issue of new matter (see Note below);
 - (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

3. Applicant's reply has overcome the following rejection(s): 35 U.S.C. 102(a) over Arminjon et al (AU 70877 or WO 96/37222).
4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: ____.

Claim(s) objected to: ____.

Claim(s) rejected: 21-38.

Claim(s) withdrawn from consideration: ____.

8. The proposed drawing correction filed on ____ is a)a) approved or b) disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s). ____.
10. Other: ____

Continuation of 2. NOTE: Claims 36 and 37 recite "effective amount". The metes and bounds of "effective amount" are unclear. The claims should recite endpoints that indicate that an "effective amount" has been administered.

Continuation of 5. does NOT place the application in condition for allowance because: Claims 21-38 remain rejected under 35 U.S.C. 103(a) as obvious over Arminjon et al (AU 708777 or WO 96/37222) for reasons of record. The proposed amendments to the claims and arguments have been carefully considered, but fail to persuade. Applicants mainly argue that Arminjon fails to disclose pertussis toxoid, inactivated poliovirus and filamentous hemagglutinin. Applicants also argue that Arminjon fails to show the adsorption of tetanus and diphtheria toxoids. However, Arminjon shows the use of pertussis anatoxin and filamentous hemagglutinin, see ex. 12. Further, the prior art of record shows that methods of adsorbing diphtheria and tetanois toxoids to aluminum salts were known, see WO 93/24148. Therefore, it would have been obvious to Arminjon to use the well known methods (such as those described in WO 93/24148) to modify the vaccine formula to improve stability. One would have been motivated by the well known concept of stabilization of vaccine antigens, evidenced in WO 93/24148. One would have had a reasonable expectation of success that adsorption would result in stability of the vaccine components.

Macy A. Brown

James C. Housel
5/14/02

JAMES HOUSEL
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600